Junshi Biosciences Reports P-III Study (FLAMES) Results of Senaparib for Advanced Ovarian Cancer
Shots:
- The P-III study (FLAMES) evaluates senaparib (PARP inhibitor) as monotx. maintenance treatment in 393 patients with FIGO stage III/IV ovarian cancer. Senaparib was jointly developed by Junshi Biosciences & IMPACT Therapeutics
- The trial met its 1EPs & the study’s interim analysis results show that senaparib can extend the PFS in patients with advanced ovarian cancer regardless of the BRCA mutation status
- Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug shortly. The fixed-dose combination capsules of senaparib and temozolomide received ODD from the US FDA in Aug 2022 for adult patients with SCLC
Ref: Globe Newswire | Image: Junshi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.